Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Oral Solid Dosage Pharmaceutical Formulation Market Outlook

The oral solid dosage pharmaceutical formulation market is projected to achieve US$ 8,95,636.0 million by 2034, up from its estimated US$ 6,29,582.6 million in 2024. Market dynamics of oral solid dosage pharmaceutical formulations are primarily influenced by factors such as the expanding elderly population that needs long-term pharmaceutical treatment, the progress of drug formulation technologies, and the growing demand for oral pharmaceuticals.

Between 2024 and 2034, the oral solid dosage pharmaceutical formulation market is anticipated to advance at a CAGR of 3.7%. Drug administration technologies have seen significant innovation in the oral solid dosage pharmaceutical formulation industry, increasing patient compliance and efficacy. The market opportunity of oral solid dosage pharmaceutical formulation to develop and change in response to the constantly changing healthcare environment.

Attributes Details
Market Value for 2024 US$ 6,29,582.6 million
Market Value for 2034 US$ 8,95,636.0 million
Market CAGR from 2024 to 2034 3.7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Innovative Manufacturing Technologies Accelerate Oral Solid Dosage Pharmaceutical Formulations Efficiency

Continuous developments in pharmaceutical production technology, such as novel equipment and methods, aid in the creation of oral solid dosage formulations that are more economical and efficient. These developments accelerate oral solid dosage pharma formulation market expansion by improving the pharmaceutical products' quality, safety, and repeatability.

Market dynamics are influenced by patients' preference for oral drugs, which are motivated by familiarity with and convenience in usage. Consumers are accepting oral solid dosage forms, which fosters oral solid dosage pharmaceutical formulation industry expansion.

The aging of the global population is increasing the prevalence of chronic illnesses. The pharmaceutical industry is expanding due to a growing demand for oral solid dosage forms that address chronic diseases.

Attributes Details
Market Value for 2019 US$ 6,29,582.6 million
Market Value for 2023 US$ 6,29,582.6 million
Market CAGR from 2019 to 2023 2.8%

The Complexities of Producing Oral Solid Dosage Pharmaceutical Formulations

Complex facilities, sophisticated machinery, and knowledgeable workers are required to produce oral solid dosage forms. Smaller pharmaceutical companies are barriers to entry due to high initial capital investment and continuous operating costs associated with production facilities.

Government policies that support generic replacement and cost-cutting efforts in healthcare systems negatively impact the oral solid dose pharmaceutical formulation market. Policies that require or reward generic replacement pressure prices and diminish the market share of branded goods.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of Adjacent Oral Solid Dosage Pharmaceutical Formulation Market

The high-potent oral solid dosage contract manufacturing market and the drug formulation market have both been studied by Future Market Insights (FMI). The data depict the projected growth of the oral solid dosage pharmaceutical formulation market from 2024 to 2034 with regard to other markets. It showcases the potential for revenue in the additional markets shown below.

Oral Solid Dosage Pharmaceutical Formulation Market:

Attributes Oral Solid Dosage Pharmaceutical Formulation Market
Value-based CAGR (2024 to 2034) 3.7%
Growth Factor The rising incidence of chronic illnesses encourages the demand for oral solid dosage pharmaceutical formulation.
Market Trend The oral solid dosage pharmaceutical formulation market is experiencing growth because consumers choose easy dosing forms.
Market Restraint Market expansion of oral solid dosage pharmaceutical formulation is inhibited by generic competition and patent expirations.

High-potent Oral Solid Dosage Contract Manufacturing Market:

Attributes High-potent Oral Solid Dosage Contract Manufacturing Market
Value-based CAGR (2024 to 2034) 7.6%
Growth Factor An increasing need for specific formulations of powerful chemicals prompts high-potent oral solid dosage contract manufacturing market expansion.
Market Trend The high-potent oral solid dosage contract manufacturing market expansion is stimulated by pharmaceutical companies outsourcing more work to take advantage of infrastructure and experience managing highly powerful APIs.
Market Restraint The high-potent oral solid dosage contract manufacturing market expansion is impeded by the high upfront expenditures of specialized infrastructure and equipment needed to handle powerful APIs.

Drug Formulation Market:

Attributes Drug Formulation Market
Value-based CAGR (2024 to 2034) 5.6%
Growth Factor The rising incidence of infectious diseases and chronic illnesses enhances demand for drug formulations.
Market Trend Drug delivery technology advancements improve patient compliance, safety, and efficacy, which advances drug formulation market expansion.
Market Restraint Market launch difficulties and other compliance burdens result from regulatory examination over the safety and efficacy of innovative formulations.

Category-wise Outlook

The segmented oral solid dosage pharmaceutical formulation market analysis is included in the following subsection. Based on comprehensive research, the immediate release sector is controlling the drug release mechanism category, and the tablets segment dominates the dosage form category.

Immediate Release Formulations Foster Pharmaceutical Sales

Segment Immediate Release
Share (2024) 43.30%

Immediate release drugs are more convenient and increase patient compliance, which boosts sales of oral solid dosage pharmaceutical formulations. Evident in prescribers' general preference for first-line therapies is the dominance of immediate release segment.

Given their applicability across a range of therapeutic domains, the immediate release segment continues to enjoy substantial demand for oral solid dosage pharmaceutical formulation. Easy administration and flexible dosage schedules are two factors supporting immediate release formulations' ongoing prominence in the oral solid dose pharmaceutical formulation market.

Tablets Segment Dominate the Sales of Oral Solid Dosage Pharmaceutical Formulation

Segment Tablets
Share (2024) 48.90%

Due to their affordability, patient familiarity, and manufacturing convenience, tablets account for the majority of sales of oral solid dosage pharmaceutical formulation. Even with many alternatives, the oral solid dosage pharmaceutical formulation industry favors tablets as a reliable, effective, and commonly recognized dosage form.

Then, follow capsules, which are more adaptable and have better drug stability, making them suitable for various formulations. Powders and granules, particularly in formulations for children and the elderly, are prevalent for individualized dosing.

Pastilles and lozenges target specific therapeutic areas and are prized for their targeted distribution and ability to increase patient compliance. Gummies are a growing trend that draws consumers looking for new and tasty substitutes, propelling the nutraceutical industry's growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Analysis

The oral solid dosage pharmaceutical formulation market can be observed in the subsequent tables, which focus on the leading regions in North America, Europe, and Asia Pacific. A comprehensive evaluation demonstrates that Asia Pacific has enormous market opportunities for oral solid dosage pharmaceutical formulation.

Oral Solid Dosage Pharma Formulation Opportunities in Asia Pacific

Countries CAGR (2024 to 2034)
China 7.2%
South Korea 6.8%
Japan 3.3%

China Industry Outlook

Given its size and changing regulatory environment, China offers many opportunities for oral solid dosage pharmaceutical formulations. The increasing emphasis on healthcare accessibility and the rising demand for oral solid dosage forms promote China's pharmaceutical industry's rapid expansion. Advancements in manufacturing and new technology are fostering China's oral solid dosage pharma formulation market expansion.

South Korea Industry Outlook

The market is expanding owing to the South Korean government's encouraging policies and investments in research and development facilities. South Korea is a desirable center for the regional manufacture and export of oral solid dosage formulations due to its advantageous location and robust intellectual property protection.

Technology and manufacturing process developments are continually raising the productivity and competitiveness of the South Korean oral solid dosage pharmaceutical formulation industry.

Japan Industry Outlook

Innovation in oral solid dosage pharmaceutical formulations is in high demand in Japan due to the country's aging population and rising rates of chronic diseases. Oral solid dose forms are developed under the influence of Japan's pharmaceutical industry, distinguished by an emphasis on tailored medicines and precision medicine.

Japan's oral solid dose pharmaceutical formulation market experiences innovation caused by ongoing investment in research and development and advances in manufacturing technology.

Market Growth Analysis of Oral Solid Dosage Pharma Formulation in Europe

Countries CAGR (2024 to 2034)
France 4.6%
Italy 3.8%
Spain 2.7%
United Kingdom 2.1%
Germany 1.6%

France Industry Outlook

Strict laws controlling oral solid dose pharmaceuticals result from the French market's emphasis on quality and safety standards. Specialized oral solid dose formulations suited to geriatric healthcare needs are in high demand due to France's aging population. The French government's healthcare policies aim to ensure that oral solid dosage pharmaceuticals are widely available to the general public.

Italy Industry Outlook

Naturally occurring oral solid dose formulations are strongly affected by the rich history of herbal therapy that Italy's pharmaceutical industry has enjoyed. Italians place a high priority on preventative healthcare, which ignites the oral solid dosage pharma formulation market that addresses illnesses related to lifestyle, like metabolic disorders.

Spain Industry Outlook

Producers of oral solid dosage pharmaceutical formulation prioritize cost-effective oral solid dosage formulations without sacrificing quality in the Spanish market, where pricing is an integral factor. Spain's regulatory framework supports environmentally sustainable approaches in the manufacturing of oral solid doses.

Collaborative efforts between Spanish pharmaceutical companies and research institutions facilitate the creation of innovative oral solid dose formulations for rare illnesses.

United Kingdom Industry Outlook

The development of customized oral solid dosage formulations based on genetic profiles is stimulated by the United Kingdom pharmaceutical market's emphasis on personalized medicine. To meet healthcare demands at a reasonable cost, the National Health Service (NHS) in the United Kingdom is a major influence on developments in oral solid dose formulation.

Germany Industry Outlook

Sustained-release formulations and other innovative oral solid dose formulation technologies are made possible by Germany's substantial expenditure on research and development. The German healthcare system has influenced the creation of user-friendly oral solid dosage formulations with clear dosing instructions, which promotes patient education and self-management.

Market Dynamics of Oral Solid Dosage Pharmaceutical Formulation in North America

Countries CAGR (2024 to 2034)
Canada 2.8%
United States 1.7%

Canada Industry Outlook

In the United States, advances in oral solid dosage pharmaceutical formulations are stimulated by the rising need for generic medications and the growing emphasis on individualized therapy. The United States' oral solid dosage pharmaceutical production landscape is changing due to the emergence of contract manufacturing organizations, or CMOs.

United States Industry Outlook

The Canada oral solid dosage pharmaceutical formulations market witnessed an increased demand for user-friendly formulations due to consumers' growing preference for over-the-counter pharmaceuticals. In Canada, particularly in rural areas, the rise of e-pharmacies and telemedicine is opening up fresh pathways for oral solid dosage pharmaceutical delivery and accessibility.

Competitive Analysis

With their knowledge and inventiveness, key oral solid dosage pharmaceutical formulation vendors rule the market in the fiercely competitive field. These oral solid dosage pharmaceutical formulation producers advance the development of pharmaceutical formulations by contributing various strengths. Pfizer, Novartis, and AstraZeneca are renowned for their broad product lines and dedication to innovation.

Merck, Eli Lilly, and AbbVie are proficient in particular therapeutic domains, augmenting the market's products. Johnson & Johnson and Teva Pharmaceuticals are important contributors to the accessibility and affordability of oral solid dosage pharmaceutical formulations.

In this highly competitive environment, oral solid dosage pharmaceutical formulation providers constantly strive to bring novel formulations, better drug delivery systems, and improve patient outcomes through ongoing research and development activities. Supply chain management, quality control, and regulatory compliance are still essential for preserving the market competitiveness of oral solid dosage pharmaceutical formulation.

The dynamic competition in the market compels oral solid dosage pharmaceutical formulation manufacturers to innovate, provide high-quality products and services, and prioritize accessibility in response to changing healthcare requirements.

Latest Advancements

Company Details
Catalent In February 2023, Catalent paid US$475 million to purchase Metrics Contract Services to increase its production capacity for oral solid dose and high-potency pharmaceuticals.
Pfizer In March 2023, Pfizer introduced Lyrica (pregabalin) in a new extended-release tablet format for the treatment of neuropathic pain.
Eli Lilly & Company Eli Lilly & Company announced the release of Trulicity, a novel bilayer tablet formulation intended to treat type 2 diabetes, in April 2023.
Farxiga The new once-daily oral tablet version of Farxiga for the treatment of type 2 diabetes and heart failure with maintained ejection fraction was announced by AstraZeneca plc in May 2023.
Novartis AG Novartis AG announced in June 2023 the launch of its new extended-release Vytorin tablet formulation for treating high cholesterol.

Pivotal Oral Solid Dosage Pharmaceutical Formulation Vendors

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences
  • Merck and Co. Inc
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La-Roche Ltd.
  • Johnson and Johnson
  • Biogen Inc.
  • Bayer AG
  • Teva Pharmaceuticals
  • Amgen Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Shire Plc.
  • Celgene Corporation
  • Astellas Pharma Inc.

Key Coverage in Oral Solid Dosage Pharmaceutical Formulation Market Report

  • Categorical Study on Tablets, Capsules, and Other Dosage Forms
  • Oral Solid Dosage Pharmaceutical Formulation Market Detailed Analysis of Current Scenario with Growth Forecasts
  • Opportunities for Oral Solid Dosage Pharmaceutical Formulation Market in India
  • Market Potential of Oral Solid Dosage Pharmaceutical Formulation in France
  • Competition Analysis of Oral Solid Dosage Pharmaceutical Formulation Manufacturers with Focus on Catalent, Pfizer, Eli Lilly & Company, and Others.

Key Segments

By Dosage Form:

  • Tablets
    • Conventional/Immediate Release
    • Modified Release
    • Chewable Tablets
    • Effervescent Tablets
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules
    • Others
  • Powders and Granules
  • Lozenges and Pastilles
  • Gummies

By Drug Release Mechanism:

  • Immediate Release
  • Delayed Release
  • Controlled Release

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Hypermarkets/Supermarkets

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

What is the Current Oral Solid Dosage Pharmaceutical Formulation Market Valuation?

The oral solid dosage pharmaceutical formulation industry to possess a valuation US$ 6,29,582.6 million in 2024.

How Big Can the Oral Solid Dosage Pharmaceutical Formulation Market Be by 2034?

The oral solid dosage pharmaceutical formulation industry is estimated to hit a worth of US$ 8,95,636.0 million by 2034.

What is the Growth Potential of the Oral Solid Dosage Pharmaceutical Formulation Market?

Through 2034, the oral solid dosage pharmaceutical formulation industry is anticipated to spur at a sluggish CAGR of 3.7%.

What Was the Historical Outlook of The Oral Solid Dosage Pharmaceutical Formulation Market?

From 2019 to 2023, the oral solid dosage pharmaceutical formulation industry registered a 2.8% HCAGR.

Which Drug Release Mechanism Category dominates in the Oral Solid Dosage Pharmaceutical Formulation Market?

The immediate release sector is scheduled to garner a share of 43.3% in 2024.

Which Dosage Form Segment to Lead the Oral Solid Dosage Pharmaceutical Formulation Market?

A 48.9% market share is expected for the tablets sector in 2024.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Manufacturer

            3.5.1.2. Mid-Level Participants (Traders)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Dosage Form, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Dosage Form, 2024 to 2034

        5.3.1. Tablets

            5.3.1.1. Conventional/Immediate Release

            5.3.1.2. Modified Release

            5.3.1.3. Chewable Tablets

            5.3.1.4. Effervescent Tablets

        5.3.2. Capsules

            5.3.2.1. Hard Gelatin Capsules

            5.3.2.2. Soft Gelatin Capsules

            5.3.2.3. Others

        5.3.3. Powders & Granules

        5.3.4. Lozenges & Pastilles

        5.3.5. Gummies

    5.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Dosage Form, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Release Mechanism

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug Release Mechanism, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug Release Mechanism, 2024 to 2034

        6.3.1. Immediate Release

        6.3.2. Delayed Release

        6.3.3. Controlled Release

    6.4. Y-o-Y Growth Trend Analysis By Drug Release Mechanism, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Drug Release Mechanism, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023

    7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Drug Stores

        7.3.4. Online Pharmacies

        7.3.5. Hypermarkets/Supermarkets

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023

    8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Dosage Form

        9.2.3. By Drug Release Mechanism

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Dosage Form

        9.3.3. By Drug Release Mechanism

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Dosage Form

        10.2.3. By Drug Release Mechanism

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Dosage Form

        10.3.3. By Drug Release Mechanism

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Dosage Form

        11.2.3. By Drug Release Mechanism

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Dosage Form

        11.3.3. By Drug Release Mechanism

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Dosage Form

        12.2.3. By Drug Release Mechanism

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Dosage Form

        12.3.3. By Drug Release Mechanism

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Dosage Form

        13.2.3. By Drug Release Mechanism

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Dosage Form

        13.3.3. By Drug Release Mechanism

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Dosage Form

        14.2.3. By Drug Release Mechanism

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Dosage Form

        14.3.3. By Drug Release Mechanism

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Dosage Form

        15.2.3. By Drug Release Mechanism

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Dosage Form

        15.3.3. By Drug Release Mechanism

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2023

            16.1.2.1. By Dosage Form

            16.1.2.2. By Drug Release Mechanism

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2023

            16.2.2.1. By Dosage Form

            16.2.2.2. By Drug Release Mechanism

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2023

            16.3.2.1. By Dosage Form

            16.3.2.2. By Drug Release Mechanism

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2023

            16.4.2.1. By Dosage Form

            16.4.2.2. By Drug Release Mechanism

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2023

            16.5.2.1. By Dosage Form

            16.5.2.2. By Drug Release Mechanism

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2023

            16.6.2.1. By Dosage Form

            16.6.2.2. By Drug Release Mechanism

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2023

            16.7.2.1. By Dosage Form

            16.7.2.2. By Drug Release Mechanism

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2023

            16.8.2.1. By Dosage Form

            16.8.2.2. By Drug Release Mechanism

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2023

            16.9.2.1. By Dosage Form

            16.9.2.2. By Drug Release Mechanism

            16.9.2.3. By Distribution Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2023

            16.10.2.1. By Dosage Form

            16.10.2.2. By Drug Release Mechanism

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2023

            16.11.2.1. By Dosage Form

            16.11.2.2. By Drug Release Mechanism

            16.11.2.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2023

            16.12.2.1. By Dosage Form

            16.12.2.2. By Drug Release Mechanism

            16.12.2.3. By Distribution Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2023

            16.13.2.1. By Dosage Form

            16.13.2.2. By Drug Release Mechanism

            16.13.2.3. By Distribution Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2023

            16.14.2.1. By Dosage Form

            16.14.2.2. By Drug Release Mechanism

            16.14.2.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2023

            16.15.2.1. By Dosage Form

            16.15.2.2. By Drug Release Mechanism

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2023

            16.16.2.1. By Dosage Form

            16.16.2.2. By Drug Release Mechanism

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2023

            16.17.2.1. By Dosage Form

            16.17.2.2. By Drug Release Mechanism

            16.17.2.3. By Distribution Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2023

            16.18.2.1. By Dosage Form

            16.18.2.2. By Drug Release Mechanism

            16.18.2.3. By Distribution Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2023

            16.19.2.1. By Dosage Form

            16.19.2.2. By Drug Release Mechanism

            16.19.2.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2023

            16.20.2.1. By Dosage Form

            16.20.2.2. By Drug Release Mechanism

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2023

            16.21.2.1. By Dosage Form

            16.21.2.2. By Drug Release Mechanism

            16.21.2.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2023

            16.22.2.1. By Dosage Form

            16.22.2.2. By Drug Release Mechanism

            16.22.2.3. By Distribution Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2023

            16.23.2.1. By Dosage Form

            16.23.2.2. By Drug Release Mechanism

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Dosage Form

        17.3.3. By Drug Release Mechanism

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. AstraZeneca Plc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. Bristol-Myers Squibb Company

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Eli Lilly and Company

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. Gilead Sciences

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. Merck & Co. Inc

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. Novartis AG

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. Pfizer Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. AbbVie Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

        18.1.9. Boehringer Ingelheim GmbH

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

                18.1.9.5.2. Product Strategy

                18.1.9.5.3. Channel Strategy

        18.1.10. F. Hoffman-La-Roche Ltd.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

                18.1.10.5.2. Product Strategy

                18.1.10.5.3. Channel Strategy

        18.1.11. Johnson & Johnson

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

                18.1.11.5.2. Product Strategy

                18.1.11.5.3. Channel Strategy

        18.1.12. Biogen Inc.

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

                18.1.12.5.2. Product Strategy

                18.1.12.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Drug Formulation Market

Published : November 2022

Explore Healthcare Insights

View Reports

Oral Solid Dosage Pharmaceutical Formulation Market